Table of Contents
ISRN Hematology
Volume 2011, Article ID 623924, 14 pages
http://dx.doi.org/10.5402/2011/623924
Research Article

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

1Department of Internal Medicine, Mercer University, Central Georgia Cancer Care, 1062 Forsyth Street, Suite 1B Macon, Georgia, GA 31201, USA
2Department of Hematology Oncology, Winship Cancer Institute, Emory University, 2365 Clifton Road, N.E. Building C, Atlanta, GA 30322, USA

Received 1 March 2011; Accepted 20 April 2011

Academic Editor: A. Takeshita

Copyright © 2011 Abeer N. AbouYabis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [47 citations]

The following is the list of published articles that have cited the current article.

  • Nadia Khan, “PTCL Therapies: A Review of Treatment and Outline of Novel Therapies,” American Journal of Therapeutics, vol. 20, no. 5, pp. 524–533, 2013. View at Publisher · View at Google Scholar
  • Kristen Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl, and Ranjana H. Advani, “Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404),” Leukemia & Lymphoma, pp. 1–16, 2013. View at Publisher · View at Google Scholar
  • Muhammad Hassaan Imam, Pareen J. Shenoy, Christopher R. Flowers, Adrienne Phillips, and Mary Jo Lechowicz, “Incidence and survival patterns of cutaneous T-cell lymphomas in the United States,” Leukemia & Lymphoma, vol. 54, no. 4, pp. 752–759, 2013. View at Publisher · View at Google Scholar
  • Laurent Gilardin, Christiane Copie-Bergman, Lionel Galicier, Véronique Meignin, Josette Brière, Julie F. Timsit, Olivier Bouchaud, Philippe Gaulard, Eric Oksenhendler, and Laurence Gérard, “Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era,” British Journal of Haematology, vol. 161, no. 6, pp. 843–851, 2013. View at Publisher · View at Google Scholar
  • Anna Czyz, Joanna Romejko-Jarosinska, Grzegorz Helbig, Wanda Knopinska-Posluszny, Lidia Poplawska, Beata Piatkowska-Jakubas, Dorota Hawrylecka, Barbara Nasilowska-Adamska, Dominik Dytfeld, Anna Lojko-Dankowska, Anna Kopinska, Piotr Boguradzki, Jan Walewski, Slawomira Kyrcz-Krzemien, Andrzej Hellmann, and Mieczyslaw Komarnicki, “Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis,” Annals of Hematology, vol. 92, no. 7, pp. 925–933, 2013. View at Publisher · View at Google Scholar
  • Xi-Mei Zhang, Ye-Xiong Li, Wei-Hu Wang, Jing Jin, Shu-Lian Wang, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Hua Ren, Li-Qiang Zhou, Xin-Fan Liu, and Zi-Hao Yu, “Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral T-Cell Lymphoma, Not Otherwise Specified,” International Journal of Radiation Oncology Biology Physics, vol. 85, no. 4, pp. 1051–1056, 2013. View at Publisher · View at Google Scholar
  • Daruka Mahadevan, Joseph M. Unger, Catherine M. Spier, Daniel O. Persky, Fay Young, Michael LeBlanc, Richard I. Fisher, and Thomas P. Miller, “Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma,” Cancer, vol. 119, no. 2, pp. 371–379, 2013. View at Publisher · View at Google Scholar
  • Shane Gangatharan, “Relapsed and refractory aggressive NHL: Time for a change,” Transfusion And Apheresis Science, vol. 49, no. 1, pp. 72–79, 2013. View at Publisher · View at Google Scholar
  • Yasuhiro Oki, Larry W. Kwak, Fredrick Hagemeister, Anas Younes, Amanda Copeland, Luis E. Fayad, Peter McLaughlin, Jatin Shah, Barbara Pro, Nathan Fowler, and Jorge Romaguera, “Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma,” British Journal Of Haematology, vol. 162, no. 1, pp. 138–141, 2013. View at Publisher · View at Google Scholar
  • Bertrand Coiffier, Massimo Federico, Dolores Caballero, Claire Dearden, Franck Morschhauser, Ulrich Jäger, Lorenz Trümper, Emanuele Zucca, Maria Gomes da Silva, Ruth Pettengell, Eckhart Weidmann, Francesco d’Amore, Hervé Tilly, and Pier Luigi Zinzani, “Therapeutic options in relapsed or refractory peripheral T-cell lymphoma,” Cancer Treatment Reviews, 2014. View at Publisher · View at Google Scholar
  • Raewyn M. Poole, “Belinostat: First Global Approval,” Drugs, 2014. View at Publisher · View at Google Scholar
  • Martin Bjerregaard Pedersen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, Michael Boe Møller, Peter Nørgaard, Preben Johansen, Elisabeth Ralfkiaer, Peter De Nully Brown, Per Boye Hansen, Bo Amdi Jensen, Jakob Madsen, Claudia Schöllkopf, and Francesco d'Amore, “Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry,” Hematological Oncology, 2014. View at Publisher · View at Google Scholar
  • S. Yun, C. N. Walker, N. D. Vincelette, and F. Anwer, “Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma,” Case Reports, vol. 2014, no. jun091, pp. bcr2014205044–bcr2014205044, 2014. View at Publisher · View at Google Scholar
  • Alessandra Dondi, Alessia Bari, Samantha Pozzi, Paola Ferri, and Stefano Sacchi, “The potential of pralatrexate as a treatment of peripheral T-cell lymphoma,” Expert Opinion on Investigational Drugs, pp. 1–8, 2014. View at Publisher · View at Google Scholar
  • Andrew M. Intlekofer, and Anas Younes, “From empiric to mechanism-based therapy for peripheral T cell lymphoma,” International Journal of Hematology, vol. 99, no. 3, pp. 249–262, 2014. View at Publisher · View at Google Scholar
  • Fangwen Zou, Zhenhua Li, Jin‑An Ma, Zhenhua Qiu, Yi‑Fang Tang, and Jiao‑Yun Zheng, “T-cell lymphoma with POEMS syndrome,” Oncology Letters, 2014. View at Publisher · View at Google Scholar
  • J. B. Cohen, and C. R. Flowers, “Optimal disease surveillance strategies in non-Hodgkin lymphoma,” Hematology, vol. 2014, no. 1, pp. 481–487, 2014. View at Publisher · View at Google Scholar
  • Owen A. O'Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D'Amore, Dejan Radeski, and Susan E. Bates, “Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice,” Clinical Cancer Research, vol. 20, no. 20, pp. 5240–5254, 2014. View at Publisher · View at Google Scholar
  • J. Yin, J. Wei, J. H. Xu, Y. Xiao, and Y. C. Zhang, “Autologous Stem Cell Transplantation as the First-Line Treatment for Peripheral T Cell Lymphoma: Results of a Comprehensive Meta-Analysis,” Acta Haematologica, vol. 131, no. 2, pp. 114–125, 2014. View at Publisher · View at Google Scholar
  • Swaminathan P. Iyer, and Francine F. Foss, “Romidepsin for the Treatment of Peripheral T-Cell Lymphoma,” Oncologist, vol. 20, no. 9, pp. 1084–1091, 2015. View at Publisher · View at Google Scholar
  • Eve Gallop-Evans, “The role of alisertib in treatment of peripheral T-cell lymphomas,” Future Oncology, pp. 150907064753000, 2015. View at Publisher · View at Google Scholar
  • Dai Chihara, Barbara Pro, Sanam Loghavi, Roberto N. Miranda, L. Jeffrey Medeiros, Michelle A. Fanale, Fredrick B. Hagemeister, Luis E. Fayad, Jorge E. Romaguera, Felipe Samaniego, Sattva S. Neelapu, Anas Younes, Nathan H. Fowler, M. Alma Rodriguez, Michael Wang, Larry W. Kwak, Peter McLaughlin, Nam H. Dang, and Yasuhiro Oki, “Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma,” British Journal of Haematology, 2015. View at Publisher · View at Google Scholar
  • Jennifer A. Crozier, Taimur Sher, Dongyun Yang, Abhisek Swaika, James Foran, Radhika Ghosh, Han Tun, Gerardo Colon-Otero, Kevin Kelly, Asher Chanan-Khan, and Sikander Ailawadhi, “Persistent disparities among patients with T-cell Non-Hodgkin Lymphomas and B-cell Diffuse Large Cell Lymphomas over 40 years: A SEER database review,” Clinical Lymphoma Myeloma and Leukemia, 2015. View at Publisher · View at Google Scholar
  • Ranjana H. Advani, Stephen M. Ansell, Mary J. Lechowicz, Anne W. Beaven, Fausto Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine Foss, Steven Horwitz, Barbara Pro, Lauren C. Pinter-Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, and Julie M. Vose, “A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial,” British Journal of Haematology, 2015. View at Publisher · View at Google Scholar
  • A-C Mamez, V Lévy, P Chevallier, D Blaise, S Vigouroux, A Xhaard, N Fegueux, N Contentin, Y Beguin, N Ifrah, C-E Bulabois, F Suarez, I Yakoub-Agha, P Turlure, E Deconink, T Lamy, J Y Cahn, A Huynh, S Maury, L M Fornecker, M Ouzegdouh, J-O Bay, G Guillerm, N Maillard, M Michallet, J-V Malfuson, J-H Bourhis, F Rialland, R Oumedaly, C Jubert, V Leblond, M Boubaya, M Mohty, and S Nguyen, “Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC),” Bone Marrow Transplantation, 2015. View at Publisher · View at Google Scholar
  • Chakkarin Burudpakdee, Huamao Mark Lin, Weiying Wang, Arpamas Seetasith, Yanyan Zhu, Vijayveer Bonthapally, and Kenneth R. Carson, “Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data,” Journal of Medical Economics, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  • Yaping Zhang, Wei Xu, Hong Liu, and Jianyong Li, “Therapeutic options in peripheral T cell lymphoma,” Journal of Hematology & Oncology, vol. 9, no. 1, 2016. View at Publisher · View at Google Scholar
  • Alison J. Moskowitz, and Steven M. Horwitz, “Targeting histone deacetylases in T-cell lymphoma,” Leukemia & Lymphoma, pp. 1–14, 2016. View at Publisher · View at Google Scholar
  • Fei Qi, Mei Dong, Xiaohui He, Yexiong Li, Weihu Wang, Peng Liu, Jianliang Yang, Lin Gui, Changgong Zhang, Sheng Yang, Shengyu Zhou, and Yuankai Shi, “Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified,” Annals of Hematology, 2016. View at Publisher · View at Google Scholar
  • Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, and Yi-Hsin Elsa Hsu, “Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review,” Plos One, vol. 11, no. 10, pp. e0161811, 2016. View at Publisher · View at Google Scholar
  • Seung-Shin Lee, Sung-Hoon Jung, Jae-Sook Ahn, Yeo-Kyeoung Kim, Min-Seok Cho, Seung-Yeon Jung, Je-Jung Lee, Hyeoung-Joon Kim, and Deok-Hwan Yang, “Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients,” Journal of Korean Medical Science, vol. 31, no. 7, pp. 1160, 2016. View at Publisher · View at Google Scholar
  • Anna Wolska-Washer, Pawel Robak, Piotr Smolewski, and Tadeusz Robak, “Emerging antibody-drug conjugates for treating lymphoid malignancies,” Expert Opinion on Emerging Drugs, pp. 1–15, 2017. View at Publisher · View at Google Scholar
  • Ling Li, Wenjing Duan, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Yu Chang, Feifei Nan, Jiaqin Yan, Zhaoming Li, Ken H. Young, and Mingzhi Zhang, “The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers,” British Journal of Haematology, 2017. View at Publisher · View at Google Scholar
  • Henrik Cederleuf, Martin Bjerregård Pedersen, Mats Jerkeman, Thomas Relander, Francesco d'Amore, and Fredrik Ellin, “The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study,” British Journal of Haematology, 2017. View at Publisher · View at Google Scholar
  • Rufino Mondejar, Cristina Pérez, Arantza Onaindia, Nerea Martinez, Julia González-Rincón, Helena Pisonero, Jose Pedro Vaqué, Laura Cereceda, Miguel Santibañez, Margarita Sánchez-Beato, and Miguel Angel Piris, “Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines,” Plos One, vol. 12, no. 5, pp. e0177524, 2017. View at Publisher · View at Google Scholar
  • Cat Hildyard, S Shiekh, Jab Browning, and Gp Collins, “Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma,” Clinical Medicine Insights: Blood Disorders, vol. 10, pp. 1179545X1770586, 2017. View at Publisher · View at Google Scholar
  • Dai Chihara, and Michelle A. Fanale, “Management of Anaplastic Large Cell Lymphoma,” Hematology/Oncology Clinics of North America, vol. 31, no. 2, pp. 209–222, 2017. View at Publisher · View at Google Scholar
  • G Fossard, F Broussais, I Coelho, S Bailly, E Nicolas-Virelizier, E Toussaint, C Lancesseur, F Le Bras, E Willems, E Tchernonog, T Chalopin, R Delarue, R Gressin, A Chauchet, E Gyan, G Cartron, C Bonnet, C Haioun, G Damaj, P Gaulard, L Fornecker, H Ghesquières, O Tournilhac, M Gomes da Silva, R Bouabdallah, G Salles, and E Bachy, “Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers,” Annals of Oncology, 2017. View at Publisher · View at Google Scholar
  • Jun Ho Yi, Seok Jin Kim, and Won Seog Kim, “Recent advances in understanding and managing T-cell lymphoma,” F1000Research, vol. 6, pp. 2123, 2017. View at Publisher · View at Google Scholar
  • Mary Gleeson, Clare Peckitt, David Cunningham, Adam Gibb, Eliza A. Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O’Hara, Andrew Wotherspoon, Ayoma Attygalle, Lia Menasce, Patrick Shenjere, Mike Potter, Mark E. Ethell, Claire Dearden, John Radford, Ian Chau, and Kim Linton, “Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital,” Leukemia & Lymphoma, pp. 1–10, 2017. View at Publisher · View at Google Scholar
  • Jennifer E. Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling Rada, Hye A. Kim, Codruta Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, and Owen A. O’Connor, “A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma,” Blood, vol. 131, no. 4, pp. 397–407, 2017. View at Publisher · View at Google Scholar
  • Alessandro Broccoli, and Pier Luigi Zinzani, “Peripheral T-cell lymphoma, not otherwise specified,” Blood, vol. 129, no. 9, pp. 1103–1112, 2017. View at Publisher · View at Google Scholar
  • Qunling Zhang, Junning Cao, Kai Xue, Xiaojian Liu, Dongmei Ji, Ye Guo, and Xiaonan Hong, “Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.,” OncoTargets and therapy, vol. 10, pp. 145–151, 2017. View at Publisher · View at Google Scholar
  • Mary Gleeson, Clare Peckitt, Ye Mong To, Laurice Edwards, Jacqueline Oates, Andrew Wotherspoon, Ayoma D Attygalle, Imene Zerizer, Bhupinder Sharma, Sue Chua, Ruwaida Begum, Ian Chau, Peter Johnson, Kirit M Ardeshna, Eliza A Hawkes, Marian P Macheta, Graham P Collins, John Radford, Adam Forbes, Alistair Hart, Silvia Montoto, Pamela McKay, Kim Benstead, Nicholas Morley, Nagesh Kalakonda, Yasmin Hasan, Deborah Turner, and David Cunningham, “CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial,” The Lancet Haematology, vol. 5, no. 5, pp. e190–e200, 2018. View at Publisher · View at Google Scholar
  • Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Mayur Uttarwar, Shih-Yuan Lee, Hong Ren, Dana A. Kennedy, and Andrei R. Shustov, “Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas,” Blood, vol. 131, no. 19, pp. 2120–2124, 2018. View at Publisher · View at Google Scholar
  • Loretta J. Nastoupil, Jean L. Koff, Leon Bernal-Mizrachi, and Christopher R. Flowers, “Non-Hodgkin Lymphoma in Adults,” The American Cancer Society's Oncology in Practice, pp. 444–462, 2018. View at Publisher · View at Google Scholar
  • Yuankai Shi, “Current status and progress of lymphoma management in China,” International Journal of Hematology, 2018. View at Publisher · View at Google Scholar